-
1
-
-
78049528573
-
Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: The prospective, multicentre Stop Imatinib (STIM) trial
-
et al; Intergroupe Français des Leucémies Myéloïdes Chroniques.
-
Mahon FX, Réa D, Guilhot J, et al. Intergroupe Français des Leucémies Myéloïdes Chroniques. Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trial. Lancet Oncol. 2010; 11: 1029-1035.
-
(2010)
Lancet Oncol.
, vol.11
, pp. 1029-1035
-
-
Mahon, F.X.1
Réa, D.2
Guilhot, J.3
-
2
-
-
0038454621
-
Persistence of malignant hematopoietic progenitors in chronic myelogenous leukemia patients in complete cytogenetic remission following imatinib mesylate treatment
-
Bhatia R, Holtz H, Niu N, et al. Persistence of malignant hematopoietic progenitors in chronic myelogenous leukemia patients in complete cytogenetic remission following imatinib mesylate treatment. Blood. 2003; 101: 4701-4707.
-
(2003)
Blood.
, vol.101
, pp. 4701-4707
-
-
Bhatia, R.1
Holtz, H.2
Niu, N.3
-
3
-
-
39149108468
-
CD34+/Ph+ cells are still detectable in chronic myeloid leukemia patients with sustained and prolonged complete cytogenetic remission during treatment with imatinib mesylate
-
Bocchia M, Ippoliti M, Gozzetti A, et al. CD34+/Ph+ cells are still detectable in chronic myeloid leukemia patients with sustained and prolonged complete cytogenetic remission during treatment with imatinib mesylate. Leukemia. 2008; 22: 426-428.
-
(2008)
Leukemia.
, vol.22
, pp. 426-428
-
-
Bocchia, M.1
Ippoliti, M.2
Gozzetti, A.3
-
4
-
-
13844251975
-
Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl
-
Weisberg E, Manley PW, Breitenstein W, et al. Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl. Cancer Cell. 2005; 7: 129-141.
-
(2005)
Cancer Cell.
, vol.7
, pp. 129-141
-
-
Weisberg, E.1
Manley, P.W.2
Breitenstein, W.3
-
5
-
-
36348968931
-
Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is effective in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in chronic phase following imatinib resistance and intolerance
-
Kantarjian HM, Giles F, Gattermann N, et al. Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is effective in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in chronic phase following imatinib resistance and intolerance. Blood. 2007; 110: 3540-3546.
-
(2007)
Blood.
, vol.110
, pp. 3540-3546
-
-
Kantarjian, H.M.1
Giles, F.2
Gattermann, N.3
-
6
-
-
73949145209
-
Nilotinib for the frontline treatment of Ph(+) chronic myeloid leukemia
-
et al; GIMEMA CML Working Party.
-
Rosti G, Palandri F, Castagnetti F, et al. GIMEMA CML Working Party. Nilotinib for the frontline treatment of Ph(+) chronic myeloid leukemia. Blood. 2009; 114: 4933-4938.
-
(2009)
Blood.
, vol.114
, pp. 4933-4938
-
-
Rosti, G.1
Palandri, F.2
Castagnetti, F.3
-
7
-
-
77953691179
-
Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia
-
et al; ENESTnd Investigators.
-
Saglio G, Kim DW, Issaragrisil S, et al. ENESTnd Investigators. Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia. N Engl J Med. 2010; 362: 2251-2259.
-
(2010)
N Engl J Med.
, vol.362
, pp. 2251-2259
-
-
Saglio, G.1
Kim, D.W.2
Issaragrisil, S.3
-
8
-
-
80052383499
-
Nilotinib versus imatinib for the treatment of patients with newly diagnosed chronic phase, Philadelphia chromosome-positive, chronic myeloid leukemia: 24-months minimum follow-up of the phase 3 randomised ENESTnd trial
-
Kantarjian HM, Hochhaus A, Saglio G, et al. Nilotinib versus imatinib for the treatment of patients with newly diagnosed chronic phase, Philadelphia chromosome-positive, chronic myeloid leukemia: 24-months minimum follow-up of the phase 3 randomised ENESTnd trial. Lancet Oncol. 2011; 12: 841-851.
-
(2011)
Lancet Oncol.
, vol.12
, pp. 841-851
-
-
Kantarjian, H.M.1
Hochhaus, A.2
Saglio, G.3
-
9
-
-
42349116071
-
Enhanced BCR-ABL kinase inhibition does not result in increased inhibition of downstream signaling pathways or increased growth suppression in CML progenitors
-
Konig H, Holtz M, Modi H, et al. Enhanced BCR-ABL kinase inhibition does not result in increased inhibition of downstream signaling pathways or increased growth suppression in CML progenitors. Leukemia. 2008; 22: 748-755.
-
(2008)
Leukemia.
, vol.22
, pp. 748-755
-
-
Konig, H.1
Holtz, M.2
Modi, H.3
-
10
-
-
14444282451
-
CD34+AC133+ cells isolated from cord blood are highly enriched in long-term culture-initiating cells, NOD/SCID-repopulating cells and dendritic cell progenitors
-
de Wynter EA, Buck D, Hart C, et al. CD34+AC133+ cells isolated from cord blood are highly enriched in long-term culture-initiating cells, NOD/SCID-repopulating cells and dendritic cell progenitors. Stem Cells. 1998; 16: 387-396.
-
(1998)
Stem Cells.
, vol.16
, pp. 387-396
-
-
De Wynter, E.A.1
Buck, D.2
Hart, C.3
-
11
-
-
33745603988
-
Monitoring CML patients responding to treatment with tyrosine kinase inhibitors: Review and recommendations for harmonizing current methodology for detecting BCR-ABL transcripts and kinase domain mutations and for expressing results
-
Hughes T, Deininger M, Hochhaus A, et al. Monitoring CML patients responding to treatment with tyrosine kinase inhibitors: review and recommendations for harmonizing current methodology for detecting BCR-ABL transcripts and kinase domain mutations and for expressing results. Blood. 2006; 108: 28-37.
-
(2006)
Blood.
, vol.108
, pp. 28-37
-
-
Hughes, T.1
Deininger, M.2
Hochhaus, A.3
-
12
-
-
34548793961
-
An international study to standardize the detection and quantitation of BCR-ABL transcripts from stabilized peripheral blood preparation by quantitative RT-PCR
-
Müller MC, Saglio G, Lin F, et al. An international study to standardize the detection and quantitation of BCR-ABL transcripts from stabilized peripheral blood preparation by quantitative RT-PCR. Haematologica. 2007; 92: 970-973.
-
(2007)
Haematologica.
, vol.92
, pp. 970-973
-
-
Müller, M.C.1
Saglio, G.2
Lin, F.3
-
13
-
-
81555214617
-
Persistence of leukemia stem cells in chronic myelogenous leukemia patients in complete cytogenetic remission on imatinib treatment for 5 years
-
Chu S, Lin A, McDonald T, et al. Persistence of leukemia stem cells in chronic myelogenous leukemia patients in complete cytogenetic remission on imatinib treatment for 5 years. Blood. 2011; 118: 5565-5572.
-
(2011)
Blood.
, vol.118
, pp. 5565-5572
-
-
Chu, S.1
Lin, A.2
McDonald, T.3
|